These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15475939)

  • 1. Chemotherapy for prostate cancer: small steps or leaps and bounds? No huzzahs just yet!
    Raghavan D
    Br J Cancer; 2004 Sep; 91(6):1003-4. PubMed ID: 15475939
    [No Abstract]   [Full Text] [Related]  

  • 2. Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer.
    Denmeade SR; Isaacs JT
    Cancer J Sci Am; 1998 May; 4 Suppl 1():S15-21. PubMed ID: 9619266
    [No Abstract]   [Full Text] [Related]  

  • 3. Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?
    Sartor O
    J Clin Oncol; 2009 May; 27(15):2417-8. PubMed ID: 19364953
    [No Abstract]   [Full Text] [Related]  

  • 4. [Topics of prostate cancer].
    Tomida K
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):43-6. PubMed ID: 19195118
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy for advanced prostate cancer: docetaxel and beyond.
    Dreicer R
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):935-46, x. PubMed ID: 16861124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
    Chua CW; Chiu YT; Yuen HF; Chan KW; Man K; Wang X; Ling MT; Wong YC
    Clin Cancer Res; 2009 Jul; 15(13):4322-35. PubMed ID: 19509141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of prostate cancer].
    Imre R
    Orv Hetil; 2005 Aug; 146(35):1839-42. PubMed ID: 16187544
    [No Abstract]   [Full Text] [Related]  

  • 8. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
    El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S
    Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prostatic cancer].
    Soulié M; Barré C; Beuzeboc P; Chautard D; Cornud F; Eschwege P; Fontaine E; Molinié V; Moreau JL; Péneau M; Ravery V; Rébillard X; Richaud P; Ruffion A; Salomon L; Staerman F; Villers A;
    Prog Urol; 2004 Nov; 14(4 Suppl 1):913, 915-55. PubMed ID: 15779654
    [No Abstract]   [Full Text] [Related]  

  • 10. Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
    Lin AM; Ryan CJ; Small EJ
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer chemotherapy in the era of targeted therapy.
    Michael A; Syrigos K; Pandha H
    Prostate Cancer Prostatic Dis; 2009; 12(1):13-6. PubMed ID: 18521103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Re: "Current role of chemotherapy in the treatment of hormone-resistant metastatic prostate cancer" by Xavier Breton, Eric Lechevallier, Christian Coulange, Prog. Urol., 2005, 15, 398-404].
    Berdah JF
    Prog Urol; 2005 Dec; 15(6):1160. PubMed ID: 16429675
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II study of spirogermanium in metastatic prostate cancer.
    Dexeus FH; Logothetis C; Samuels ML; Hossan B
    Cancer Treat Rep; 1986 Sep; 70(9):1129-30. PubMed ID: 3742495
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
    Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
    J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy of solid tumors.
    Petersen M; Taylor JD
    Med J Aust; 1978 Mar; 1(6):340. PubMed ID: 661705
    [No Abstract]   [Full Text] [Related]  

  • 16. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for advanced prostate cancer: 25 years later.
    Logothetis CJ; Millikan R
    J Clin Oncol; 2008 May; 26(15):2423-4. PubMed ID: 18487561
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate cancer: the role of hormonal therapy.
    Salesi N; Carlini P; Ruggeri EM; Ferretti G; Bria E; Cognetti F
    J Exp Clin Cancer Res; 2005 Jun; 24(2):175-80. PubMed ID: 16110748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hormone refractory prostate cancer.
    Lin AM; Small EJ
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):187-91. PubMed ID: 18685361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer chemotherapy. Interview by Christine McKillop.
    Sternberg CN
    Eur Urol; 2007 Apr; 51(4):1136-8. PubMed ID: 17250951
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.